Publications by authors named "Katsuhiro Takabayashi"
Article Synopsis
- The 2021 WHO classification of CNS tumors combines histopathology and molecular profiling to effectively differentiate between adult malignant brain tumors, particularly gliomas and primary CNS lymphomas (PCNSL).
- A new intraoperative integrated diagnostic (i-ID) system has been developed that enhances traditional frozen-section diagnosis with a qPCR-based genotyping assay, crucial for therapeutic decision-making.
- After testing the i-ID system on 101 patients, it showed high reliability, matching permanent diagnoses in nearly all cases, thus proving to be a valuable tool for accurate classification of adult malignant CNS tumors.
Purpose: Molecular targeted therapy using BRAF and/or MEK inhibitors has been applied to BRAFV600E-mutant high-grade gliomas (HGG); however, the therapeutic effect is limited by the emergence of drug resistance.
Experimental Design: We established multiple paired BRAFV600E-mutant HGG patient-derived xenograft models based on tissues collected prior to and at relapse after molecular targeted therapy. Using these models, we dissected treatment-resistant mechanisms for molecular targeted therapy and explored therapeutic targets to overcome resistance in BRAFV600E HGG models in vitro and in vivo.